GIP Hormone Reduces Inflammation-Induced Nausea Through CGRP Brain Circuits

GIP receptor activation suppressed both inflammation-driven food aversion (via CGRP neurons) and food intake through separate brain circuits.

Province, Haley S et al.·bioRxiv : the preprint server for biology·2025·low-moderateAnimal StudyAnimal Study
RPEP-13117Animal Studylow-moderate2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
low-moderate
Sample
N=Not specified (animal study)
Participants
Mice (various transgenic lines)

What This Study Found

GIP receptor agonism blocks IL-1β-induced aversion via parabrachial CGRP neurons while preserving anorexia through a separate circuit.

Key Numbers

Mouse study; IL-1-beta used to induce inflammation; parabrachial CGRP neurons required for CTA but not anorexia; dorsal vagal complex GIPR required for anorexia but not anti-aversion.

How They Did This

Preclinical mouse study using GIP agonists, IL-1β challenge, in vivo CGRP neuron activity recording, and circuit-specific manipulations.

Why This Research Matters

Understanding how GIP separates nausea from appetite suppression could explain why tirzepatide causes less nausea than pure GLP-1 drugs.

The Bigger Picture

This explains a key advantage of GIP/GLP-1 dual agonists — the GIP component may reduce the nausea that limits GLP-1-only drug tolerability.

What This Study Doesn't Tell Us

Preprint — not yet peer-reviewed. Mouse study may not fully translate to human experiences of nausea and appetite.

Questions This Raises

  • ?Does this explain why tirzepatide has fewer GI side effects than semaglutide?
  • ?Could selective GIP agonism be used specifically to treat chemotherapy-induced nausea?

Trust & Context

Key Stat:
Distinct circuits GIP agonism separates anti-aversion (via CGRP neurons) from appetite suppression through different brain pathways
Evidence Grade:
Preprint of a preclinical study — compelling mechanistic data but awaiting peer review and human translation.
Study Age:
Preprint posted in 2025, providing cutting-edge mechanistic insight into dual-incretin pharmacology.
Original Title:
GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits.
Published In:
bioRxiv : the preprint server for biology (2025)
Database ID:
RPEP-13117

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Why does tirzepatide cause less nausea than semaglutide?

This study suggests the GIP component of tirzepatide specifically blocks nausea-related brain circuits (CGRP neurons) while preserving appetite suppression.

What are parabrachial CGRP neurons?

Brain cells that produce CGRP and control feelings of sickness, food aversion, and nausea — they are a key target for reducing treatment-related nausea.

Read More on RethinkPeptides

Cite This Study

RPEP-13117·https://rethinkpeptides.com/research/RPEP-13117

APA

Province, Haley S; Hayes, Nikolas W; Leong, Nathan A; Lorch, Carolyn M; Pekerman, Alexandra; Xia, Jessica L; Beutler, Lisa R. (2025). GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits.. bioRxiv : the preprint server for biology. https://doi.org/10.1101/2025.08.12.669936

MLA

Province, Haley S, et al. "GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits.." bioRxiv : the preprint server for biology, 2025. https://doi.org/10.1101/2025.08.12.669936

RethinkPeptides

RethinkPeptides Research Database. "GIP receptor agonism suppresses inflammation-induced aversio..." RPEP-13117. Retrieved from https://rethinkpeptides.com/research/province-2025-gip-receptor-agonism-suppresses

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.